Nirmal Bang: Dishman Carbogen Q2 Review - India CRAMS Yet To Recover
Dishman Carbogen Amcis formulation development facility (image: Company website)

Nirmal Bang: Dishman Carbogen Q2 Review - India CRAMS Yet To Recover

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Nirmal Bang Report

Dishman Carbogen Amcis Ltd. reported Q2 FY21 revenue at Rs 4,395 million, 15% below our and 7% below the consensus estimate.

The revenue was down 2.1% YoY and 7% QoQ. The revenue was affected as India contract research and manufacturing services (CRAMs) business did not resume operations and the marketable molecule segment declined by 30% QoQ.

We expect India CRAMS revenue to normalize from FY22 onwards as remediation efforts for the Bavla manufacturing facility are in progress.

Click on the attachment to read the full report:

Nirmal Bang Dishman Carbogen Amcis-Q2FY21 Result Update-17 November 2020.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.